Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Acute Pain D059787 3 associated lipids
Vascular System Injuries D057772 2 associated lipids
Orthostatic Intolerance D054971 1 associated lipids
Headache Disorders, Secondary D051271 1 associated lipids
Overweight D050177 11 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Holt S et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. 2007 Eur. J. Pharmacol. pmid:17397826
Rodella LF et al. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. 2005 Eur. J. Pharmacol. pmid:15680264
Peroni RN et al. Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. 2004 Eur. J. Pharmacol. pmid:15189776
Wheal AJ and Randall MD Effects of hypertension on vasorelaxation to endocannabinoids in vitro. 2009 Eur. J. Pharmacol. pmid:19100733
Beltramo M and Piomelli D Anandamide transport inhibition by the vanilloid agonist olvanil. 1999 Eur. J. Pharmacol. pmid:9920187
Stengel PW et al. Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. 1998 Eur. J. Pharmacol. pmid:9754939
Vann RE et al. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. 2009 Eur. J. Pharmacol. pmid:19470387
Ralevic V et al. Cannabinoid activation of recombinant and endogenous vanilloid receptors. 2001 Eur. J. Pharmacol. pmid:11672565
Wallace MJ et al. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. 2002 Eur. J. Pharmacol. pmid:12359270
Kelley BG and Thayer SA Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. 2004 Eur. J. Pharmacol. pmid:15288572
O'Sullivan SE et al. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. 2005 Eur. J. Pharmacol. pmid:15659311
Del Arco I et al. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. 2002 Eur. J. Pharmacol. pmid:12409011
Wagner JA et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. 2001 Eur. J. Pharmacol. pmid:11448486
Orliac ML et al. Increases in vanilloid TRPV1 receptor protein and CGRP content during endotoxemia in rats. 2007 Eur. J. Pharmacol. pmid:17482593
Wheal AJ et al. Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries. 2012 Eur. J. Pharmacol. pmid:22154756
Bouaboula M et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. 2005 Eur. J. Pharmacol. pmid:15987634
Nilsson O et al. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. 2006 Eur. J. Pharmacol. pmid:16928371
McQueen DS et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. 2004 Eur. J. Pharmacol. pmid:15140635
Fowler CJ et al. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. 2004 Eur. J. Pharmacol. pmid:15145699
Romano MR and Lograno MD Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery. 2012 Eur. J. Pharmacol. pmid:22429572
Wiley JL et al. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. 2014 Eur. J. Pharmacol. pmid:24858366
Mendizábal VE et al. Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. 2001 Eur. J. Pharmacol. pmid:11567656
Bermúdez-Siva FJ et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. 2006 Eur. J. Pharmacol. pmid:16423347
Shimasue K et al. Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel. 1996 Eur. J. Pharmacol. pmid:8904088
de Lago E et al. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. 2004 Eur. J. Pharmacol. pmid:14744610
García Mdel C et al. Role of CGRP and GABA in the hypotensive effect of intrathecally administered anandamide to anesthetized rats. 2006 Eur. J. Pharmacol. pmid:16472800
Basavarajappa BS et al. Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. 2003 Eur. J. Pharmacol. pmid:12679143
Wiley J et al. Discriminative stimulus effects of anandamide in rats. 1995 Eur. J. Pharmacol. pmid:7781695
Bondarenko AI et al. Direct activation of Ca and voltage-gated potassium channels of large conductance by anandamide in endothelial cells does not support the presence of endothelial atypical cannabinoid receptor. 2017 Eur. J. Pharmacol. pmid:28327344
Pelorosso FG et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. 2009 Eur. J. Pharmacol. pmid:19022239
Jackson SN et al. Volatile anesthetics and endogenous cannabinoid anandamide have additive and independent inhibitory effects on alpha(7)-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. 2008 Eur. J. Pharmacol. pmid:18242598
Walentiny DM et al. The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. 2011 Eur. J. Pharmacol. pmid:21300050
Baldassano S et al. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. 2008 Eur. J. Pharmacol. pmid:18234188
Fride E and Mechoulam R Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. 1993 Eur. J. Pharmacol. pmid:8384116
Lau AH and Chow SS Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. 2003 Eur. J. Pharmacol. pmid:12620517
García Mdel C et al. Impaired hypotensive responses induced by intrathecally injected drugs in fructose-fed rats. 2013 Eur. J. Pharmacol. pmid:23499700
Peroni RN et al. Participation of CGRP and prostanoids in the sex-linked differences of vascular anandamide effects in mesenteric beds of Sprague-Dawley rats. 2007 Eur. J. Pharmacol. pmid:17169358
Mechoulam R et al. Endocannabinoids. 1998 Eur. J. Pharmacol. pmid:9831287
Russo R et al. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. 2007 Eur. J. Pharmacol. pmid:17434479
Barg J et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. 1995 Eur. J. Pharmacol. pmid:8749028
Ghasemi M et al. Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum. 2006 Eur. J. Pharmacol. pmid:16824514
Gifford AN et al. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). 1999 Eur. J. Pharmacol. pmid:10556675
Stamer WD et al. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. 2001 Eur. J. Pharmacol. pmid:11730719
Zygmunt PM et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. 2000 Eur. J. Pharmacol. pmid:10822052
Wiley JL et al. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. 2005 Eur. J. Pharmacol. pmid:15740725
Zaniewska M et al. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. 2006 Eur. J. Pharmacol. pmid:16730696
Stella N and Piomelli D Receptor-dependent formation of endogenous cannabinoids in cortical neurons. 2001 Eur. J. Pharmacol. pmid:11513837
Costa B and Colleoni M Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol. 2000 Eur. J. Pharmacol. pmid:10781666
Varga K et al. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. 1995 Eur. J. Pharmacol. pmid:7589169
Alptekin A et al. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. 2010 Eur. J. Pharmacol. pmid:20171208
Randall MD et al. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. 1997 Eur. J. Pharmacol. pmid:9314035
Randall MD and Kendall DA Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. 1997 Eur. J. Pharmacol. pmid:9369375
Burkey TH et al. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. 1997 Eur. J. Pharmacol. pmid:9384246
Calignano A et al. Potentiation of anandamide hypotension by the transport inhibitor, AM404. 1997 Eur. J. Pharmacol. pmid:9389389
Begg M et al. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. 2002 Eur. J. Pharmacol. pmid:11755170
Giuffrida A et al. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. 2000 Eur. J. Pharmacol. pmid:11080522
Marichal-Cancino BA et al. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. 2013 Eur. J. Pharmacol. pmid:24076186
Wise LE et al. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. 2007 Eur. J. Pharmacol. pmid:17217945
Adinolfi B et al. Anticancer activity of anandamide in human cutaneous melanoma cells. 2013 Eur. J. Pharmacol. pmid:24041928
Martin BR et al. Assessment of structural commonality between tetrahydrocannabinol and anandamide. 2002 Eur. J. Pharmacol. pmid:11790376
Zheng Y et al. Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system. 2014 Eur. J. Pharmacol. pmid:24508383
Calignano A et al. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. 2001 Eur. J. Pharmacol. pmid:11426841
Kopczyńska B et al. Anandamide enhances expression of heat shock proteins Hsp70 and Hsp25 in rat lungs. 2011 Eur. J. Pharmacol. pmid:21756900
Lisboa SF et al. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. 2008 Eur. J. Pharmacol. pmid:18691568
Fride E et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. 2001 Eur. J. Pharmacol. pmid:11426843
Lay L et al. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. 2000 Eur. J. Pharmacol. pmid:10720647
Sordelli MS et al. Cyclooxygenase-2 prostaglandins mediate anandamide-inhibitory action on nitric oxide synthase activity in the receptive rat uterus. 2012 Eur. J. Pharmacol. pmid:22554772
Sprague J et al. Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. 2001 Eur. J. Pharmacol. pmid:11448475
Ndong C et al. Cloning and pharmacological characterization of the dog cannabinoid CBâ‚‚receptor. 2011 Eur. J. Pharmacol. pmid:21871882
Di Marzo V et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. 2001 Eur. J. Pharmacol. pmid:11408034
Di Marzo V et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. 2000 Eur. J. Pharmacol. pmid:11040343
Rácz I et al. Anandamide effects on 5-HT(3) receptors in vivo. 2008 Eur. J. Pharmacol. pmid:18775693
Wiley JL et al. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. 1998 Eur. J. Pharmacol. pmid:9760024
Lichtman AH et al. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. 1998 Eur. J. Pharmacol. pmid:9797029
Thors L and Fowler CJ Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. 2009 Eur. J. Pharmacol. pmid:19715690
Stanley CP et al. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. 2013 Eur. J. Pharmacol. pmid:24120371
Stengel PW et al. Inhaled anandamide reduces leukotriene D4-induced airway obstruction in guinea pigs. 2007 Eur. J. Pharmacol. pmid:17166495
Calignano A et al. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. 1997 Eur. J. Pharmacol. pmid:9537804
Costa B et al. Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. 2002 Eur. J. Pharmacol. pmid:12163107
de Lago E et al. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. 2002 Eur. J. Pharmacol. pmid:12163112
Pertwee RG et al. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. 1995 Eur. J. Pharmacol. pmid:7713152
Gratzke C et al. Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. 2010 Eur. Urol. pmid:19147270
Prieto D Editorial comment on: localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. 2010 Eur. Urol. pmid:19147273
Wiley JL et al. A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. 2004 Exp Clin Psychopharmacol pmid:15301634
Burkey RT and Nation JR (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. 1997 Exp Clin Psychopharmacol pmid:9260067
Prestifilippo JP et al. Inhibition of salivary secretion by activation of cannabinoid receptors. 2006 Exp. Biol. Med. (Maywood) pmid:16946411
De Petrocellis L et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. 2007 Exp. Cell Res. pmid:17428469
Frampton G et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. 2010 Exp. Cell Res. pmid:20347808
Grimaldi C et al. Anandamide inhibits adhesion and migration of breast cancer cells. 2006 Exp. Cell Res. pmid:16343481
Jumpertz R et al. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea--specific role of oleoylethanolamide. 2010 Exp. Clin. Endocrinol. Diabetes pmid:20429051
Matsuda S et al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. 1997 Exp. Eye Res. pmid:9245900
Köse S et al. Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. 2018 Exp. Hematol. pmid:29030083
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Hansen HS Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. 2010 Exp. Neurol. pmid:20353771
Greco R et al. The endocannabinoid system and migraine. 2010 Exp. Neurol. pmid:20353780
Bhaskaran MD and Smith BN Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. 2010 Exp. Neurol. pmid:20144892
Kreutz S et al. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. 2007 Exp. Neurol. pmid:17010339
Bir LS and Ercan S Effects of intrathecal anandamide on somatosensory evoked responses in rats. 2006 Exp. Neurol. pmid:16289169
Solbrig MV et al. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. 2005 Exp. Neurol. pmid:16022863
Morgese MG et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. 2007 Exp. Neurol. pmid:17900568